On-Demand Webinars
-
Process Development For CGT: How Soon Is Too Soon?
10/29/2026
Deciding when cell and gene therapy programs should commit to process development, and how early choices shape commercial readiness, is a question industry leaders examine from several different vantage points.
-
Pre-Developed Assays For Cell And Gene Therapies
10/29/2026
Pre-developed, fast-qualify assay libraries aim to expedite and harmonize analytical development for cell and gene therapies, offering a different route than building each assay from scratch.
-
Unlocking Hidden Efficiencies In Cell And Gene Therapy Manufacturing
10/28/2026
Identify hidden bottlenecks, cut batch variability, reduce costs, and protect quality. Learn strategies to streamline GMP transitions and speed commercialization.
-
Scaling Spray-dried Dispersions For Commercial Success: Scale, Capacity, Supply
10/26/2026
Scaling SDDs takes more than larger batches. Explore how early planning and process understanding can preserve performance and reduce commercialization risk.
-
Bioconjugation Scale-Up: Data-Driven Strategies From 10 L To 500 L
10/23/2026
Data-driven scale-up of ADC bioconjugation depends on matching mixing and temperature conditions. Solvent compatibility of single-use components and production-scale economics round out the decisions.
-
Plastic Components And Systems Used In Pharmaceutical Manufacturing
10/23/2026
Ensuring regulatory compliance for manufacturing components requires rigorous chemical characterization and risk-based testing to safeguard patient safety and product quality.
- Viral Vector for Rare and Ultra-rare Disease 10/20/2026
-
Building a Global Manufacturing Network: "Dual-Sourcing" Commercial Strategies
10/19/2026
EU entry after FDA approval puts launch timing and supply continuity at risk. QP release, importation pathways, and distributed manufacturing networks all shape whether a biologic reaches the market predictably.
-
Linking Biomarkers To Clinical Proof-Of-Mechanism
10/19/2026
Proving CNS delivery and target engagement in neurodegenerative therapies requires aligned clinical pharmacology and bioanalysis, from model selection to validated assays.
-
Precision At Scale: Optimizing Cell-Free DNA Manufacturing For mRNA Vaccines
10/16/2026
Backbone-free enzymatic DNA templates can improve polyA integrity, long-transcript quality, and RNA yield, with implications for IVT timelines and regulation.